Moneycontrol PRO
LAMF
LAMF

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities

    Net Sales are expected to increase by 5.2 percent Y-o-Y (up 7.7 percent Q-o-Q) to Rs 13,628.1 crore, according to ICICI Securities.

  • Sun Pharma’s hair loss drug Leqselvi faces uncertain road to launch

    Sun Pharma Q3: Management indicated that the launch of Leqselvi could be delayed until December 2026 if the company does not secure a favourable judgment in the ongoing patent infringement case.

  • Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth

    Sun Pharma's Q3 earnings may see a slight setback in margins, pressured by increased R&D expenses and a lower contribution from cancer drug Revlimid.

  • Sun Pharma Q1 Preview: Strong US, domestic sales to aid profit growth but high R&D to drag margins

    Sun Pharma's performance in the US market will be driven by ramp-up of Revlimid, resumption of supplies from Mohali unit and growth in its specialty portfolio. Back home, its robust foothold in the chronic segment promises to fuel double-digit growth.

  • Sun Pharma Q1 preview: Subdued growth on weak Taro numbers, muted US sales

    Analysts expect a ramp-up in select specialty products to offset some impact of restrictions at Halol and Mohali plants for Sun Pharma.

  • Sun Pharma Q1 PAT seen up 8.6% YoY to Rs 2,238.8 cr: Nirmal Bang

    Net Sales are expected to increase by 9.5 percent Y-o-Y (up 7.8 percent Q-o-Q) to Rs 11,784.7 crore, according to Nirmal Bang.

  • Sun Pharma Q3 PAT may dip 4% YoY to Rs 19,767 cr: Nirmal Bang

  • Q2 Preview | Sun Pharma consolidated net may drop 4% on high R&D costs

  • Sun Pharma Q1 Results Preview | Profit may rise 16%; revenue likely to dip 13%

  • Sun Pharma Q1 PAT may dip 15.5% YoY to Rs 1,673.1 cr: ICICI Direct

  • Sun Pharmaceutical Industries Q1 PAT seen up 23.7% YoY to Rs 1,786.1 cr: Prabhudas Lilladher

  • Sun Pharma Q3 Preview: Consolidated PAT to gain 10% YoY while revenue to rise 11%

  • Sun Pharmaceutical Industries Q1 PAT seen up 17.5% YoY to Rs 1,346.7 cr: KRChoksey

  • un Pharma Q1 PAT seen up 23.7% YoY to Rs 1,417.3 cr: ICICI Direct

  • Sun Pharma to announce Q4 results today; here what brokerages expect

  • Sun Pharma Q4 PAT seen up 82.2% YoY to Rs. 1,462.7 cr: Sharekhan

  • Sun Pharma's profit, revenue to rise in Q3; EBITDA margin may remain stable

  • Sun Pharma Q3 PAT seen up 56.7% YoY to Rs. 1,431.5 cr: Yash Securities

  • Sun Pharma Q3 PAT seen up 44.4% YoY to Rs 1,319 cr: ICICI Direct

  • Sun Pharma Q2 preview: Taro may hit revenue growth, trends in specialty portfolio key to watch

  • Sun Pharma Q4 profit, revenue expected to report healthy growth on low base

  • Sun Pharma Q2 PAT seen up 12% YoY to Rs. 1,114.8 cr: Emkay

  • Sun Pharma Q1 PAT seen up 12.3% YoY to Rs. 762.6 cr: Prabhudas Lilladher

  • Global brokerages stay positive on Sun Pharma, see 14-31% upside after Q4

  • Sun Pharma Q4 PAT may dip 36.1% YoY to Rs. 837 cr: Prabhudas Lilladher

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347